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Abstract
Background: Cardiometabolic profile is usually altered in obesity. Interestingly, the consumption of flavanol-
rich foods might be protective against those metabolic alterations.
Objective: To evaluate the postprandial cardiometabolic effects after the acute consumption of cocoa extract
before and after 4 weeks of its daily intake. Furthermore, the bioavailability of cocoa extract was investigated.
Design: Twenty-four overweight/obese middle-aged subjects participated in a 4-week intervention study. Half
of the volunteers consumed a test meal enriched with 1.4 g of cocoa extract (415 mg flavanols), while the rest
of the volunteers consumed the same meal without the cocoa extract (control group). Glucose and lipid
profile, as well as blood pressure and cocoa metabolites in plasma, were assessed before and at 60, 120, and
180 min post-consumption, at the beginning of the study (Postprandial 1) and after following a 4-week 15%
energy-restricted diet including meals containing or not containing the cocoa extract (Postprandial 2).
Results: In the Postprandial 1 test, the area under the curve (AUC) of systolic blood pressure (SBP) was
significantly higher in the cocoa group compared with the control group (p0.007), showing significant
differences after 120 min of intake. However, no differences between groups were observed at Postprandial 2.
Interestingly, the reduction of postprandial AUC of SBP (AUC_Postprandial 2-AUC_Postprandial 1) was
higher in the cocoa group (p0.016). Furthermore, cocoa-derived metabolites were detected in plasma of the
cocoa group, while the absence or significantly lower amounts of metabolites were found in the control group.
Conclusions: The daily consumption of cocoa extract within an energy-restricted diet for 4 weeks resulted in a
greater reduction of postprandial AUC of SBP compared with the effect of energy-restricted diet alone and
independently of body weight loss. These results suggest the role of cocoa flavanols on postprandial blood
pressure homeostasis.
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O
besity is considered one of the major public
health problems associated with cardiovascular
mortality (1). In that situation, different fasting
and postprandial metabolic markers are altered contri-
buting to the development of the obesity-associated
comorbidities such as diabetes, insulin resistance, hy-
pertension, atherosclerosis, and dyslipidaemia, among
others (2, 3). Interestingly, the prescription of nutritional
strategies as well as lifestyle changes, such as the re-
duction of energy intake and adherence to healthy dietary
patterns, reduces the risk of suffering from cardiometa-
bolic disorders (4, 5). On the other hand, the intake of
plant extracts, which are rich on polyphenols, is receiving
especial attention in the protection against obesity-
associated comorbidities (6). In this context, cocoa is
one of the richest sources of polyphenols with claimed
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benefits on blood pressure (7, 8), insulin resistance (7, 9),
lipid profile (911), endothelial dysfunction or oxidative
stress (10, 1214), and inflammation (9, 1518). Such
therapeutic effects have been attributed to some of the
bioactive compounds occurring in cocoa, mainly flava-
nols, which are the most abundant polyphenols in this
seed (19). Flavanols in cocoa are found as monomers
(()-epicatechin and ()-catechin) and procyanidins
(20). Furthermore, cocoa also contains other bioactive
compounds such as methylxanthines (caffeine and theo-
bromine) and minerals (magnesium, copper, iron, etc.)
with potential healthy properties (21).
In order to establish a relationship between cocoa
consumption and healthy benefits through physiological
mechanisms, flavanols from cocoa need to be absorbed
into the circulation (22). Bioavailability depends on
different factors such as food matrix, physical state, and
the degree of flavanol polymerisation (23). Cocoa mono-
meric and some oligomeric flavanols are stable in the
stomach and small intestine (24, 25) and are rapidly
absorbed appearing in plasma between 30 and 60 min
post-consumption (20, 26). Afterwards, glucoronidation,
sulphation, and methylation of the monomeric flavanols in
the liver and in the small intestine produce O-glucoronidated,
O-sulphated, and O-methylated flavanol derivates in
plasma (23). Once in the bloodstream, these metabolites
undergo additional conjugations in the liver and returned
back to the small intestine by enterohepatic circulation
(23). Procyanidins are poorly absorbed; only procyanidin
dimer B2 has been detected in human plasma (24, 25).
Unabsorbed flavanols reach the colon where after the
degradation by the intestinal microbiota and the transfor-
mations to phenolic acids are then absorbed into the
circulation (27). In addition, phase II metabolites are
excreted into the bile where after the bacterial enzyme
activities are reabsorbed into the circulation. Finally,
metabolites are transferred from the bloodstream to the
kidneys to be excreted in urine (23).
On the other hand, the intake of a food component
could have a different effect when consumed first time or
when consumed regularly during a determined period of
time (28). Surprisingly, it has not yet been well documen-
ted if the cardiometabolic response to the acute consump-
tion of cocoa extract could be persistent with time or
it could be influenced by its regular consumption during
a determined period of time, resulting in an adaptive or
tachyphylactic effect.
The present research is a substudy carried out within a
clinical trial (NCT01596309), whose principal purpose was
to evaluate the effect of consuming ready-to-eat meals
containing cocoa extract under a moderate energy
restricted diet for 4 weeks on the general nutritional status,
as well as on cardiometabolic and oxidative markers of
middle-aged obese subjects. The obtained results eviden-
ced the improvement of oxidised low-density lipoprotein
cholesterol levels (13). In addition, the prescribed energy-
restricted diet reduced the adiposity as well as improved
blood pressure, routine blood biochemical profile, and
25-hydroxyvitamin D levels (29, 30).
The aim of the present study was specifically focussed on
analysing the postprandial response of the acute con-
sumption of cocoa extract during the immediate 3 h of
intake on routine blood biochemical and blood pressure
markers before and after 4 weeks of its daily consumption.
Furthermore, the bioavailability of the cocoa extract
within the ready-to-eat meals provided in the study was
evaluated measuring cocoa-derived metabolites in plasma.
Methods
Subjects
From the main study (n50), 24 volunteers (58.2 (5.2)
years) took part in the present substudy: 12 allocated in the
control group (6 men and 6 women) and the remaining
12 in the cocoa group (5 men and 7 women) as shown in
Fig. 1A.
All the participants gave written informed consent to
participate in the trial. To be enrolled in the study subjects
needed to be between 50 and 80 years old, with a body
mass index (BMI) of 27.035.5 kg/m2 and maintaining
a stable weight (B5% of variation) within the previous
3 months to the intervention. Subjects suffering from the
following conditions were not included: gastrointestinal
disease, hepatic diseases, diabetes, cancer or inflammatory
disease, food allergies, or cognitive and psychiatric altera-
tions. Also, individuals following a weight loss treatment,
hormone replacement, anti-inflammatory, hypocholes-
terolaemic or blood pressure lowering treatments were
not allowed to participate. Subjects taking antidepressant
drugs, antioxidant-rich supplements, medication that
could influence appetite or nutrient absorption, inability
to follow-up the intervention and smokers were also
excused from the study.
Study design
The study was carried out in the Metabolic Unit of the
University of Navarra (Pamplona, Spain). The trial was
approved by the Research Ethics Committee of the
University of Navarra (ref. no 006/2012) and followed
the Helsinki Declaration guidelines. Furthermore, it was
registered at www.clinicaltrials.gov (NCT01596309).
CONSORT guidelines 2010 were considered.
One week before the beginning of the intervention,
volunteers were required to exclude cocoa and cocoa-
containing products from their habitual diet. In addition,
3 days before the beginning of the study, all of the vol-
unteers were required to follow a low-polyphenolic diet
which was restricted in fruits and vegetables and excluded
polyphenol rich foods such as cocoa, coffee, tea, infusions,
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botanical or antioxidant-rich supplements as well as juices
and alcoholic drinks.
The postprandial study was performed on the first
day (Postprandial 1) and the last day (Postprandial 2) of a
4-week nutritional intervention (Fig. 1B). The procedure
consisted of the consumption of a test meal (a ready-to-eat
dish and a dessert) containing 1.4 g of cocoa extract, or
the same meal without cocoa extract, depending on the
group allocation. The experiment was carried out after a
10-h overnight fast. Blood samples and blood pressure
measurements were taken just before the consumption of
the test meal (time 0) and at 60, 120 and 180 min post-
consumption. The postprandial test was repeated after
4 weeks (day 28) of following an energy-restricted diet
(15%E) including or not including the daily consump-
tion of ready-to-eat meals containing 1.4 g/day of cocoa
extract, depending on the experimental group alloca-
tion (Fig. 1B). The energy-restricted diet consisted of
45% of the total caloric value from carbohydrates, B30%
from lipids and 2225% from proteins, as explained
elsewhere (13).
The randomisation to participate in the main study was
performed using the ‘random between 1 and 2’ function in
the Microsoft Office Excel (Microsoft Iberica, Madrid,
Spain). Boxes in which the meals were provided had the
same appearance and differed only on the code label,
ensuring the double-blind protocol. The dietary restriction
of foods containing cocoa and polyphenol rich foods was
maintained during the 4 weeks of intervention and
volunteers were also asked not to change their phy-
sical activity patterns. Three days before the end of the
intervention, volunteers were prescribed to consume
predetermined types of test meals from the variety of
meals they had available for the last week of the interven-
tion, in order to make all the volunteers reach the endpoint
of the study in similar nutritional conditions avoiding
nutritional interferences.
Test meals
The postprandial test included a meal containing 1.4 g of
cocoa extract or the same meal without cocoa extract,
which was based on a ready-to-eat dish and dessert:
courgette cream (300 g) and chocolate custard (150 g).
The whole meal provided a total energy of 365 kcal and
was composed of (in grams and proportions (%)) 34.2 g
(7.6%) of carbohydrates, 20.9 g (4.6%) of lipids, 8.9 g
(2.0%) of proteins, 4.9 g (1.1%) of fibre, 377.7 g (83.9%)
of water, and 4.1 g (0.9%) of ash.
Fig. 1. A) Flow chart of the participants. B) Study diagram.
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Characterisation of cocoa extract
The cocoa extract and the analytical characterisation
were supplied by Nutrafur S.A. (Murcia, Spain). The
composition of 1.4 g of cocoa extract as mean (SD) was
as follows: 140.4 (7.1) mg of theobromine, 645.3 (32.3)
mg of total polyphenols as catechin, 414.3 (20.7) mg
of flavanols as catechin, 153.4 (7.7) mg of epicatechin,
14.6 (0.7) mg of catechin, 99.4 (5.0) mg of procyanidin
B2, 13.4 (0.7) mg of procyanidin B1, and 133.5 (6.7) mg
of oligomeric procyanidins. Total polyphenol content was
determined by FolinCiocalteu method, and flavanoids
and theobromine were analysed by high-performance
liquid chromatography (HPLC), whose analytical proce-
dures have been described in detail elsewhere (13).
Body weight and blood biochemical analyses
Body weight was measured underwear in an overnight
fasting condition using dual-energy X-ray absorptiometry
following manufacturer?s instructions (Lunar Prodigy,
software version 6.0, Madison, WI). Blood samples were
drawn before (time 0) and after the consumption of tested
meals (60, 120 and 180 min) through an intravenous
catheter inserted into an antecubital vein using ethylene-
diaminetetraacetic acid (EDTA) and CLOT tubes
(BD Vacutainer†). After each extraction, samples were
centrifuged in order to obtain plasma and serum aliquots
(15 min, 1,500 g, 48C), which were then stored at 80 8C
until analysis. Plasma glucose, total cholesterol (Total-c),
and high-density lipoprotein cholesterol (HDL-c) were
measured by colorimetric procedures in a Pentra C200
autoanalyser (Horiba Medical, Montpellier, France).
Blood pressure determination
Blood pressure was determined immediately before the
consumption of the test meal (time 0) and at 60, 120 and
180 min post-consumption using an automatic monitor
device (Intelli Sense. M6, OMRON Healthcare, Hoofd-
dorp, the Netherlands). Measures were carried out always
in the same arm, sitting on a chair with the cuff at the
same level as the heart and with the arm in relaxed
position. Between measurements, volunteers were main-
tained in resting conditions, free of any alterations in a
quiet and temperature-controlled room.
Analysis of cocoa extract derived metabolites
The assessment of cocoa-derived metabolites in plasma
was performed to evaluate the bioavailability of cocoa
extract and to assess the adherence of the volunteers
to the intervention, as well as to compare the metabolite
concentration in plasma before and after 4 weeks of
daily cocoa consumption. Fourteen cocoa-derived meta-
bolites were targeted in plasma of cocoa group in the
Postprandial 1 test and the same metabolites were
measured in the Postprandial 2 in cocoa and control
groups. The analysed metabolites were: catechin, epica-
techin, methyl-epicatechin-glucuronidate, procyanidin
B2, methyl-catechin-glucuronidate, catechin-sulphate,
epicatechin-glucuronidate, epicatechin-sulphate, 3-O-
methyl-epicatechin, methyl-epicatechin-O-sulphate, 3,7-
dimethyluric acid, 1-methylxanthine, 3-methylxanthine,
and theophylline.
Chemicals and reagents
Procyanidin B2 was purchased from Extrasynthese
(Genay, France). ()-catechin and ()-epicatechin were
purchased from Fluka Co. (Buchs, Switzerland) while
3-methylxanthine and 3,7-dimethyluric acid were from
Sigma Aldrich (St. Louis, MO). Cathecol was used as
internal standard (IS). Methanol (HPLC grade), acetoni-
trile (HPLC grade) and acetic acid were all provided by
Scharlau Chemie (Barcelona, Spain). Ortho-phosphoric
acid (85%) was purchased from Panreac (Barcelona,
Spain). Water was of milli-Q quality (Millipore Corp,
Bedford, MA).
Phenolic metabolites’ extraction
Phenolic metabolites were extracted by using microelution
plates (Waters, Milford, MA) packed with 2 mg of OASIS
HLB sorbent (Waters) following the method described by
Serra et al. (31) with minor modifications. Briefly, the wells
were sequentially conditioned by using 250mL of methanol
and 250 mL of milli-Q water:acetic acid (99.8:0.2, v/v).
Then, 200 mL of plasma mixed with 350 mL of phosphoric
acid 4% and 50 mL of catechol (IS) at 0.5 mg/L were loaded
into the wells. After that, the clean-up of the plates was
sequentially done with 200 mL of milli-Q water and 200 mL
of milli-Q water:acetic acid (99.2:0.2, v/v) to eliminate any
interference that the sample might contain. Finally, the
elution of the retained metabolites was performed with
250 mL of acetone:milli-Q water:acetic acid (70:29.5:0.5,
v/v/v). A 5 mL portion of the eluted metabolites was
directly injected into the HPLCMS/MS (Agilent Tech-
nologies, Palo Alto, U.S.A.).
Theophylline metabolites extraction
Theophylline metabolites were extracted following the
method described by Ogawa et al. (32) with some minor
modifications. Thus, 50 mL of plasma was mixed with
100 mL of acetonitrile, vortexed for 1 min and centrifuged
for 5 min at 1,000 rpm. Pellets were removed, and solvent
was evaporated to dryness under nitrogen flow rate.
Finally, samples were reconstituted with 50 mL of milli-Q
water:acetic acid (99.9:0.1, v/v) and were analysed by
HPLC-MS/MS.
HPLCMS/MS measurements
The HPLCMS/MS system consisted of an Agilent 1200
Series instrument (Agilent Technologies, Palo Alto, CA)
using a Zorbax SB-Aq column (3.5 mm, 150 mm2.1 mm
i.d.) equipped with a Pre-Column Zorbax SB-C18 (3.5 mm,
15 mm2.1 mm i.d.) and coupled to a triple quadrupole
6410 also from Agilent.
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Two chromatographic methods were used to analyse the
whole range of metabolites. To carry out the analysis of
phenolic metabolites the column was kept at 258C and the
flow rate was 0.4 mL/min. The composition for solvent
A was milli-Q water:acetic acid (99.8:0.2 v/v) while for
solvent B, acetonitrile. The elution gradient was 010 min,
555% B; 1011 min, 5580% B; 1112 min, 80% B; 1213
min, 805% B; and 5 min post-time. On the other hand, to
analyse theophylline metabolites, milli-Q water:acetic acid
(99.8:0.2 v/v) was used as solvent A and acetonitrile as
solvent B. The elution gradient was 02 min, 310% B;
34 min, 1050% B; 45 min, 5095% B; 56 min, 95% B;
66.5 min, 953% and 2 min post-time. The flow rate was
held at 0.5 mL/min throughout all the run time.
Ionisation was performed by electrospray (ESI) in the
negative mode and the source parameters were drying gas
temperature 3508C, flow rate 12 L/min, gas nebuliser
pressure 45 psi, and the capillary voltage 4,000 V. The
selected reaction monitoring (SRM) transitions and the
instrumental parameters for each compound are reported
(Supplementary Table 1). Due to the lack of standards of
some metabolites, they were tentatively quantified by using
the calibration curves corresponding to their phenolic pre-
cursors as is specified in Supplementary Table 2. Quality
parameters are reported (Supplementary Table 2). Results
are expressed as nmol/L of each metabolite/compound in
the plasma sample. Values under the limit of quantification
(LOQ) are expressed as ‘n.q.’ (not quantified), while values
under the limit of detection (LOD) are showed as ‘n.d.’
(not detected).
Statistical analyses
Data were analysed using the SPSS 15.0 for Windows
statistical program (SPSS, Inc., Chicago, IL) considering
results with p values less than 0.05 as statistically sig-
nificant. Normality of the variables was assessed by the
ShapiroWilk test. Data are expressed as mean (SD).
Comparisons between baseline and the endpoint of the
intervention were analysed by the student paired t test or
the Wilcoxon test. The comparisons between both groups
were performed by parametric t test or MannWhitney U
test, depending on the normality of the variables. Area
under the curve (AUC) was calculated for blood biochemi-
cal markers, blood pressure, and cocoa extractderived
metabolites in plasma according to the trapezoid rule (33)
in GraphPad Prism version 5 for Windows (GraphPad
Software, San Diego, CA). Thus, the AUC was determined
per hour, and then the sum of the 3 AUCs was performed.
For cocoa metabolites, the AUC was calculated when at
least the metabolites were quantifiable at one time-point.
However, to perform the statistical analysis and to
calculate the p value derived from the comparison of
AUC of control and cocoa groups, the original data of each
participant was used, even if it was under the LOQ or
LOD. Analysis of covariance (ANCOVA) was performed
to compare groups in the Postprandial 1and Posprandial 2
adjusted for the baseline value of each variable in each test
and baseline weight or weight change (Dendpoint-
baseline) when appropriate. The comparisons of the
AUC changes (Postprandial 2  Postprandial 1) between
groups were adjusted for the changes of each assessed
variable at fasting and Dweight. Covariates were included
in the ANCOVA analysis to avoid results bias. The
comparisons between Postprandial 1 and Postprandial
2 at different time points were evaluated by repeated
measures analysis of variance (ANOVA) for multiple
comparisons by Bonferroni correction. Although some
metabolites were under the LOQ or LOD, repeated
measures ANOVA were performed with those values
when appropriate.
Results
Subjects
Twenty-three subjects of the initial twenty-four [58.2 (5.2)
years] completed the study. Awoman from the cocoa group
was removed due to dietary non-compliance (self-
reported), and hence 11 subjects finished the study under
cocoa treatment (Fig. 1A). This volunteer was also
excluded from the statistical analyses following per proto-
col criteria. Although differences were observed at baseline
in several of the assessed variables, none of these were at
statistically significant levels (Table 1). As expected, body
weight was significantly reduced in both interven-
tion groups, control: 2.8 (1.3) and cocoa: 2.7 (0.9),
Table 1. Anthropometric and clinical characteristics of subjects
from control and cocoa groups at baseline
Baseline
Variables Control (n12) Cocoa (n11) pa
Age 57 (4.9) 59 (5.4) 0.332
Weight (kg) 83.5 (9.8) 83.3 (10.9) 0.970
BMI (kg/m2) 30.2 (2.2) 31.4 (2.6) 0.258
Waist (cm) 103.7 (4.8) 105.2 (6.8) 0.523
SBP (mmHg) 116 (14.4) 122 (16.5) 0.303
DBP (mmHg) 76 (8.9) 80 (7.1) 0.326
Glucose (mg/dL) 96.2 (8.6) 99.1 (7.0) 0.387
Insulin (mU/mL) 7.6 (5.1) 9.2 (7.4) 0.559
Total-c (mg/dL) 220.6 (37.4) 237.0 (64.8) 0.460
HDL-c (mg/dL) 55.5 (15.2) 52.2 (8.2) 0.533
Data presented as mean (SD).
aComparison between control and cocoa groups.
pB0.05 was considered significant.
BMI: body mass index; DBP: diastolic blood pressure; HDL-c: high-
density lipoprotein cholesterol; SBP: systolic blood pressure; Total-c:
total cholesterol.
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after the 4-week intervention period, without statistical
differences between groups.
Postprandial glucose and lipid metabolism response
Differences between groups were not found, neither in the
AUC of glucose nor in the lipid metabolism variables
during Postprandial 1 and Postprandial 2 tests. Both
groups reported lower AUC of total cholesterol and
HDL-c at Postprandial 2 (Table 2), but no differences
were observed when the AUC changes (Postprandial 2 
Postprandial 1) were compared between groups (Table 2).
Postprandial blood pressure response
The AUC concerning SBP was significantly (p0.007)
higher in the cocoa group comparedwith the control group
during the Postprandial 1 adjusted for baseline SBP and
baseline weight (Table 2). Specifically, repeated measures
analysis revealed that the consumption of the cocoa-
supplemented meal resulted in a significantly higher
(p0.018) SBP levels at 120 min post-consumption
when compared to control group (Fig. 2). However, no
differences were found along time in the SBP within
the cocoa or control groups in the Postprandial 1. In the
Postprandial 2, no statistical differences concerning AUC
of SBP were found between groups adjusted for baseline
SBP in the Postprandial 2 and weight change (Table 2).
When the AUC of Postprandial 1 and Postprandial 2 was
compared within each group, the AUC of SBP decreased
significantly in both groups, (control p0.015 and
cocoa p0.001), but interestingly, the reduction of AUC
(Postprandial 2  Postprandial 1) in the cocoa group was
significantly higher (p0.016) in comparison to the
control group when controlled for the change of baseline
SBP and weight change during the 4 weeks (Fig. 3).
Concerning the AUC of DBP, no differences were
noted between groups neither in the Postprandial 1 nor in
the Postprandial 2 (Table 2). When the AUC of DBP was
compared within the same group between Postprandial 1
and 2, significant reduction was observed in both groups
(control pB0.001, cocoa p0.001). However, when the
AUC changes (Postprandial 2  Postprandial 1) for
DBP were compared between groups, no significant
differences were found (Table 2).
Cocoa-derived metabolites in plasma
Fourteen metabolites related with cocoa intake were
measured in plasma of cocoa group at Postprandial 1
and in plasma of control and cocoa groups at Post-
prandial 2. Data are presented when at least in one of the
groups the metabolite was quantifiable (Table 3). Meta-
bolites were monomeric and dimeric flavanols (catechin,
epicatechin, and procyanidin B2), alkaloid metabolites
(3-methylxanthine, 1-methylxanthine, 3,7-dimethyluric
acid, and theophylline) and flavanol phase II metabolites
(methyl-epicatechin-glucuronidate, methyl-catechin- glu-
curonidate, catechin-sulphate, epicatechin- glucuronidate,
epicatechin-sulphate, methyl-epicatechin-O-sulphate, and
3-O-methyl-epicatechin).
Except theophylline, cocoa-derived metabolites were
not detected in fasting condition (time 0) at the beginning
of the study. Interestingly, cocoa-derived metabolites were
Table 2. Area under the curve of biochemical and blood pressure variables at Postprandial 1 and 2
Postprandial 1 (day 1) Postprandial 2 (day 28)
AUC Control (n12) Cocoa (n11) pa Control (n12) Cocoa (n11) pb pc pd pe
Glucose (mg h/dL) 286.9 (43.5) 314.8 (29.1) ns 292.9 (37.3) 314.4 (33.6) ns ns ns ns
Insulin (mU h/dL)f 75.9 (60.4) 97.6 (73.8) ns 68.6 (50.3) 77.0 (48.5) ns ns ns ns
Total-c (mg h/dL) 664.5 (120.2) 714.1 (194.7) ns 551.0 (88.1) 577.2 (138.8) ns B0.001 0.001 ns
HDL-c (mg h/dL) 161.7 (44.0) 154.0 (25.4) ns 141.0 (25.6) 134.3 (23.8) ns 0.011 0.001 ns
SBP (mmHg h) 338.0 (31.0) 376.0 (46.6) 0.007 317.0 (28.8) 340.0 (36.6) ns 0.015 0.001 0.016
DBP (mmHg h) 226.0 (19.8) 240.0 (22.8) ns 205.0 (17.9) 220.0 (21.7) ns B0.001 0.001 ns
Data presented as unadjusted mean (SD). Comparisons between both groups were performed with an independent t test or MannWhitney U test and
comparisons between Postprandial 1 and 2 were analysed by paired student t test or Wilcoxon test, depending on the normality of the variables.
ANCOVA univariate analyses adjusted for fasting value of each assessed variable, baseline weight, and ^weight differently combined were performed.
pB0.05 was considered as significant.
a AUC control vs. AUC cocoa group in Postprandial 1, adjusted for baseline value of the assessed variable in Postprandial 1 and baseline weight.
b AUC control vs. AUC cocoa group at Postprandial 2, adjusted for baseline value of the assessed variable at Postprandial 2 and Dweight.
c AUC control group in the Postprandial 1 vs. AUC control group in the Postprandial 2.
d AUC cocoa group in the Postprandial 1 vs. AUC cocoa group in the Postprandial 2.
e Difference in the change (Postprandial 1 and Postprandial 2) in AUC between control and cocoa groups, adjusted for Dbaseline value of the variable
(baseline value at Postprandial 2-fasting value at Postprandial 1) and Dweight.
f No-normally distributed variables.
AUC: area under the curve; DBP: diastolic blood pressure; HDL-c: high-density lipoprotein cholesterol; ns: not significant; SBP: systolic blood pressure;
Total-c: total cholesterol; Dweight: weight change.
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detected in plasma samples of cocoa consumers after the
meal consumption in both postprandial trials, while in
the control group the absence or significantly lower
concentration of those metabolites was found in the
Postprandial 2 (Table 3).
As expected, a significant variation was noted along the
180 min post-consumption in the cocoa-derived metabo-
lites. The highest concentration of metabolites was found
at 60 and 90 min post-consumption (Table 3). The repeated
measures ANOVA revealed no differences in the amount of
metabolites between Postprandial 1 and Postprandial
2 except for 3-methylxanthine and theophylline, which
presented higher amounts in the Postprandial 2 (Table 3).
Similarly, when the AUC of Postprandial 1 and Postpran-
dial 2 was compared between groups, significantly higher
AUC of 3-methylxanthine (pB0.001) and theophylline
(p0.001) was detected in the second postprandial test
(Table 3).
Discussion
In this study, the postprandial effect of consuming ready-
to-eat meals containing a cocoa extract was studied before
and after 4 weeks of following a moderate hypocaloric diet
including the daily consumption of ready-to-eat meals
supplemented with cocoa extract. One of the major find-
ings of this trial was the different postprandial response of
SBP to the acute intake of cocoa extract before and
after the daily consumption of cocoa extract for 4 weeks.
Fig. 2. Systolic blood pressure before (time 0) and after meal consumption (60, 120, and 180 min) in control (n12) and cocoa
(n11) groups.
Fig. 3. Comparison between groups of the change of area
under the curve (AUC) of systolic blood pressure (Post-
prandial 2  Postprandial 1).
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Table 3. Cocoa-derived metabolites in plasma before (time 0) and after meal consumption (60, 120, and 180 min)
Time (min) pa
Cocoa metabolites (nmol/L) 0 60 120 180 p 0180? p P1P2
p
0180?
P1P2
AUC
(nmol h/L) p AUCb
Procyanidin B2e
Cocoa-P1 n.d. 3.2 (1.8) 3.1 (1.1) n.q. B0.001 n.s. n.s. 7.6 (3.1) ns
Cocoa-P2 n.d. 3.1 (1.3) n.q. n.q. 7.3 (3.7)
Control-P2 n.d. n.d. n.d. n.d. 
Methyl-catechin-glucuronidate
Cocoa-P1 n.d. 42.6 (23.9) 43.2 (12.8) 39.2 (11.9) B0.001 n.s. n.s. 105.9 (38.2) ns
Cocoa-P2 n.q. 55.2 (18.0) 62.6 (45.1) 41.4 (12.8) 143.7 (58.87)
Control-P2 n.d. n.q. n.q. n.q. 
Epicatechin-glucuronidate
Cocoa-P1 n.d. 1,346.8 (677.8) 1,267.6 (499.7) 968.1 (360.7) B0.001 n.s. n.s. 3,098.4 (1,234.3) ns
Cocoa-P2 104.4 (63.9) 1,576.5 (478.9) 1,371.1 (366.4) 998.6 (388.1) 3,499.2 (955.0)
Control-P2 14.4 (29.9) 40.6 (22.3) 44.4 (21.9) 63.9 (101.3) 124.2 (82.4)
Catechin-sulphatee
Cocoa-P1 n.d. 133.7 (53.3) 106.0 (40.1) 65.8 (24.2) B0.001 n.s. n.s. 272.6 (85.6) ns
Cocoa-P2 12.1 (17.0) 138.1 (51.0) 106.8 (48.7) 62.6 (45.9) 282.2 (110.2)
Control-P2 n.d. n.d. n.d. n.d. 
Methyl-epicatechin-O-sulphate
Cocoa-P1 n.d. 353.7 (138.5) 353.3 (111.7) 276.9 (59.7) B0.001 n.s. n.s. 845.4 (249.0) ns
Cocoa-P2 24.2 (12.1) 397.5 (108.4) 385.6 (79.8) 284.6 (80.9) 937.5 (185.9)
Control-P2 n.q. n.d. 13.9 (4.0) 16.5 (26.1) 36.3 (19.8)
Epicatechin-sulphate
Cocoa-P1 n.d. 2,847.6 (1,034.2) 2,970.6 (958.2) 2,074.4 (524.2) B0.001 n.s. n.s. 6,734.1 (2,164.3) ns
Cocoa-P2 152.2 (98.8) 3,311.2 (1,029.2) 3,374.3 (996.0) 2,201.2 (885.0) 7,862.1 (1,862.2)
Control-P2 n.q. 92.2 (42.6) 80.0 (20.8) 107.0 (175.7) 229.7 (135.1)
3-O-methyl-epicatechin
Cocoa-P1 n.d. 137.8 (51.8) 136.6 (47.0) 92.2 (37.9) B0.001 n.s. n.s. 320.5 (104.2) ns
Cocoa-P2 n.q. 151.1 (40.7) 147.8 (33.3) 110.1 (36.6) 358.2 (76.6)
Control-P2 n.d. n.q. n.q. n.q. 
3,7-dimethyluric acid
Cocoa-P1 n.d. 66.1 (138.3) n.q. n.q. 0.002 n.s. n.s. 135.4 (171.8) ns
Cocoa-P2 n.q. 68.0 (43.4) 61.9 (32.1) 77.6 (82.7) 176.8 (117.4)
Control-P2 n.d. n.q. n.q. n.q. 
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Table 3. (Continued )
Time (min) pa
Cocoa metabolites (nmol/L) 0 60 120 180 p 0180? p P1P2
p
0180?
P1P2
AUC
(nmol h/L) p AUCb
3-methylxanthine
Cocoa-P1 n.d.c 458.3 (190.8)c 634.0 (146.8)c 705.5 (158.3)c B0.001 B0.001 n.s. 1,445.0 (328.1) B0.001
Cocoa-P2 881.1 (310.9)d 1,301.1 (394.5)d 1,386.4 (427.7)d 1,560.9 (528.1)d 3,908.5 (1,146.7)
Control-P2 335.2 (303.5) 542.2 (315.7) 592.7 (331.4) 680.0 (412.8) 1,642.5 (983.8)
Theophyllinee
Cocoa-P1 121.3 (212.3)c 285.5 (190.2)c 360.7 (143.3)c 391.0 (164.9)c B0.001 0.013 n.s. 902.3 (512.3) 0.001
Cocoa-P2 726.2 (742.8)d 858.7 (563.9)d 854.4 (689.4)d 867.4 (555.7)d 2,509.8 (1,876.9)
Control-P2 339.7 (341.3) 398.7 (328.7) 407.9 (291.1) 415.5 (329.8) 1,184.2 (949.0)
Data presented as unadjusted mean (SD). When a mean value was not quantifiable or no detectable in control group at 0, 60, 120, or 180 min, the real values were used, although been under the limit of
quantification or detection, to perform statistical analysis where appropriate. AUC was calculated when at least the metabolite was above the limit of quantification in one time-point. In those cases, also the
corresponding pAUC is reported. p AUC was calculated using the original values of each participant where appropriate. Comparisons between P1 and P2 were analysed by paired student t test or Wilcoxon
test, according to the normality of the variables. pB0.05 was considered as significant.
 Not possible to calculate AUC.
a p values of the repeated measures ANOVA.
b AUC of cocoa group at Postprandial 1 vs. AUC of cocoa group at Postprandial 2.
c,d Cocoa group at Postprandial 1 vs. Cocoa groups at Postprandial 2 at each time-point by multiple comparison by Bonferroni correction.
e Non-normally distributed variables.
AUC: area under the curve; n.d: not detected; n.s.: not significant; n.q.: not quantified; P1: Postprandial 1; P2: Postprandial 2.
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In the Postprandial 1, the intake of cocoa extract resulted
in a significantly higher acute AUC of SBP, showing
significant differences at 120 min post-consumption when
compared to the control group. Although none of the
differences at baseline were at statistically significant levels,
it cannot be discarded that the differences of baseline SBP
between both groups could influence the result in some
manner. However, to minimise that influence, analyses
were adjusted for baseline SBP levels when appropriate as
reported in Table 2. On the other hand, when the
postprandial test was repeated after the daily consumption
of cocoa extract for 4 weeks, the effect was not maintained,
suggesting an adaptive process of the postprandial SBP
when cocoa is acutely consumed after a regular intake
during a short period of time. Nevertheless, the present
results should be viewed with caution because although
significant differences were observed respect to the control
group, no significant differences between baseline SBP and
the SBP at 120 min of consuming the cocoa extract were
found. Most of the reports showing a significant effect on
SBP after a nutritional intervention have been observed in
subjects suffering from hypertension (34, 35). However,
cocoa is associated with blood pressurelowering proper-
ties, and indeed there are studies reporting a reduction of
SBP levels after an intervention with cocoa in normoten-
sive individuals. In this sense, Heiss et al. compared the
effect of cocoa intake between young (n22) and elderly
(n20) normotensive subjects reporting a significant
reduction of blood pressure in elderlygroup (36). Similarly,
Grassi et al. observed that in a 1-week crossover study the
supplementation with different doses of cocoa resulted in a
significant reduction of SBP in overweight normotensive
subjects (37). On the other hand, studies involving the
acute administration of cocoa have reported a reduction
(38, 39) or no changes of SBP (40, 41). It seems that most of
the studies have been performed in subjects with hyperten-
sion or in special situations favouring a metabolic altera-
tion. This is the case of the studies carried out by Basu et al.
or Grassi et al., where subjects were diabetic or were
subjected for an atherosclerotic environment. In those
studies, cocoa flavanols were able to reduce the SBP levels
(38, 39). However, there are studies observing an increment
of SBP after cocoa intake compared to the treated group.
In this sense, De Gottardi et al. observed that blood
pressure increased in cirrhotic patients after 30 min of
consuming a liquid meal containing 0.55 g of dark
chocolate/kg body weight (42). Similarly, West et al.
assessed the acute effect of consuming 22 g of cocoa (814
mg flavanol) following the regular intake of cocoa during 4
weeks. These researchers observed a higher SBP at 2 h
post-consumption in comparison with a flavanol free
group, although no differences were found in blood
pressure after the regular cocoa intake (43). The increment
of SBP after cocoa intake could be attributed to theobro-
mine content, which is the most important methylxanthine
in cocoa, and although it does not have the same
stimulating effect as caffeine, it has similar properties
such as the stimulation of heart rate (44, 45).
More important is the result obtained concerning
SBP when the differences between both postprandial tests
(AUC_Postprandial 2 and AUC_Postprandial 1) were
compared between both groups. Interestingly, a greater
reduction of postprandial SBP was observed in cocoa con-
sumers after 4 weeks of daily cocoa consumption inde-
pendently of body weight loss and controlled for baseline
SBP levels, suggesting that postprandial reduction of SBP
could be affected by the daily consumption of cocoa
extract. Although the subjects of the study were over-
weight/obese, overall the population of the study resulted
normotensive. It is well known that obesity predisposes
to suffer from hypertension (46). However, according to
scientific evidence not all obese subjects are necessarily
metabolically altered or hypertensive. Those subjects are
known as ‘metabolically healthy obese’ (47, 48). This term
refers to subjects suffering from obesity without metabolic
alterations (48). Although the population of this study
is normotensive, the energy-restricted diet was able to
reduce SBP levels reporting a higher reduction in cocoa-
supplemented group. This result supports the blood
pressurelowering properties of cocoa flavanol intake in
obese individuals without current hypertension (37).
In our previously published data, subjects supplemented
with 1.4 g/day of cocoa extract and the control group
reduced significantly fasting SBP levels after the 4 week
intervention. However, no differences were found beteween
them (13). Thus, in that case, the reduction of fasting SBP
levels was attributed to the weight loss diet followed by
the volunteers during the 4 weeks and not to the cocoa
consumption (13). However, in this research, the postpran-
dial SBP was assessed, revealing that it may be affected
after a regular consumption of the cocoa extract (7, 8).
On the other hand and as expected, a reduction was
observed in the AUC of routine blood biochemical
markers, but without differences between groups. This
result should be attributed to the weight loss obtained after
following the 15% energy-restricted diet (49).
Importantly, the measurement of food-derived metabo-
lites in plasma is an useful method to assess the bioavail-
ability of nutrients (23) and the compliance of food intake
(10, 50, 51). In this study, 14 cocoa-derived metabolites
were analysed in plasma. Ten metabolites were detected
and quantified in cocoa consumers and 5 in the control
group. As expected, cocoa metabolites in the plasma
samples of cocoa consumers were detected during both
postprandial tests, and the absence or significantly lower
concentration of those metabolites were detected in
control group. This outcome demonstrated the bioavail-
ability of cocoa extract flavanols within the ready-to-eat
meals as well as the compliance of the volunteers during
the intervention. In accordance with other studies, most of
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the metabolites were phase II metabolites such as catechin
and epicatechin-sulphates, methylates, and glucoronidates
(52) but also alkaloid metabolites were detected in both
groups. Epicatechin and catechin were not quantifiably
intact after 1 h of the cocoa extract consumption, probably
due to a rapid metabolisation in sulphates, methylates, and
glucoronidates. Interestingly, the procyanidin B2 was
detected in plasma of cocoa consumers (24).
Focussing on the cocoa group, 3-methylxanthine and
theophylline levels were significantly in higher concentra-
tions in the second postprandial period. This phenomenon
could be due to the half-life of theobromine and derivatives
in the circulation. While the half-life of flavanols in plasma
varies between 6 and 8 h with a maximum concentration at
12 h post-consumption (24), the half-life of theobromine
and derivatives varies between 7.5 and 10 h, with a
maximum concentration at 2 h post-consumption (53).
The presence of some cocoa-derived metabolites in the
control group could be explained because of the presence
of other flavanol sources in the diet such as apples, pome
fruits, etc. The concentration of those flavanols in subjects
from control group was in significantly lower amounts, in
accordance with the results obtained in other studies (50).
The metabolites reported in this study have been already
identified in other cocoa-related studies (25, 50, 54).
Finally, it is important to highlight the strengths and
limitations of the present investigation. First, a crossover
design would have been appropriate because each cross-
over patient serves as his/her own control reducing the
effect of confounding covariates. Nevertheless, the cross-
over design was declined because the volunteers would
present a weight loss due to the prescribed energy-
restricted diet. In this sense, weight change would have
been a confounding factor since weight loss would not have
been the same in the first phase comparing with the second
phase of the crossover. For this reason, parallel study was
designed. Second, blood pressure measurements were not
performed in series of three consecutive measurements in
order to avoid overwhelming the volunteers during the
postprandial period, which can be considered as a weak-
ness of this study. Third, the assessment of cocoa-derived
metabolites in plasma is considered a reliable method to
evaluate the nutritional compliance of the volunteers.
Nevertheless, not to consider the effect of cocoa extract
beyond the 180 min post-consumption is a limitation of
this study.
Conclusions
The intake of cocoa extract within an energy-restricted
diet during 4 weeks revealed a higher reduction of
postprandial AUC of SBP when compared to control
group. In addition, cocoa-derived metabolites were de-
tected in plasma of cocoa consumers suggesting the
bioavailability of cocoa compounds within the ready-to-
eat meals. Overall, this research provides a new evidence to
understand the role of cocoa flavanols on postprandial
cardiometabolic markers including blood pressure.
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